Iglicki Matias

Iglicki Matias, Khoury Marina, Donato Lucas, Quispe Diego Jose, Negri Hermino Pablo, Melamud Javier Ignacio

This study compared subretinal aflibercept, ranibizumab, and bevacizumab for submacular hemorrhage in nAMD. All three anti-VEGF agents showed similar efficacy and safety profiles, suggesting comparable treatment outcomes.

Iglicki Matias, Khoury Marina, Melamud Javier Ignacio, Donato Lucas, Barak Adiel, Quispe Diego Jose et al.

This study found subretinal aflibercept, combined with pneumatic displacement/tPA for nAMD-related submacular hemorrhage, significantly reduced subsequent anti-VEGF injections compared to intravitreal delivery, suggesting better disease management.

Iglicki Matias, Busch Catharina, Lanzetta Paolo, Sarao Valentina, Veritti Daniele, Rassu Nicolò et al.

This study found dexamethasone implants for diabetic macular edema are equally effective in vitrectomized and non-vitrectomized eyes, meaning prior vitrectomy doesn't alter treatment response.

Mezad-Koursh Daphna, Klein Ainat, Rosenblatt Amir, Teper Roth Sharon, Neudorfer Meira, Loewenstein Anat et al.

This study found peripapillary hyperreflective ovoid mass-like structures (PHOMS) are the most common cause of pseudopapilledema in children. Identifying PHOMS with EDI-OCT allows early detection and follow-up of these potential precursors to optic nerve head drusen.

Iglicki Matias, Busch Catharina, Zur Dinah, Okada Mali, Mariussi Miriana, Chhablani Jay Kumar et al.

Dexamethasone implants improved vision in diabetic macular edema, but treatment-naive eyes gained significantly more vision than those refractory to anti-VEGF, suggesting better outcomes with earlier use.